ライフサイエンスコーパス: pancreatic ductal adenocarcinoma

1 he operative treatment of pancreatic cancer (pancreatic ductal adenocarcinoma).

2 -492, which is recognised as a biomarker for pancreatic ductal adenocarcinoma.

3 o be used for the detection and prognosis of pancreatic ductal adenocarcinoma.

4 s) and cell-free DNA (cfDNA), with regard to pancreatic ductal adenocarcinoma.

5 ment of treatment response, and follow-up of pancreatic ductal adenocarcinoma.

6 mples obtained from patients with metastatic pancreatic ductal adenocarcinoma.

7 mportant prognostic factor for patients with pancreatic ductal adenocarcinoma.

8 and increased survival compared with typical pancreatic ductal adenocarcinoma.

9 preoperative therapy and pancreatectomy for pancreatic ductal adenocarcinoma.

10 rapy in 730 evaluable patients with resected pancreatic ductal adenocarcinoma.

11 new standard of care following resection for pancreatic ductal adenocarcinoma.

12 tility and is believed to be dysregulated in pancreatic ductal adenocarcinomas.

13 tor 1 (NTSR1) is overexpressed in most human pancreatic ductal adenocarcinomas.

14 ety and efficacy in patients with metastatic pancreatic ductal adenocarcinoma and a poor PS.

15 by CXCR4 causes immune suppression in human pancreatic ductal adenocarcinoma and colorectal cancer b

16 he mechanisms of immunotherapy resistance in pancreatic ductal adenocarcinoma and discuss strategies

17 pancreatic neoplasms are resectable stage I pancreatic ductal adenocarcinoma and high-risk precursor

18 analysis in a family with multiple cases of pancreatic ductal adenocarcinoma and identify a germline

19 of comprehensive genomic characterization of pancreatic ductal adenocarcinoma and its precursor lesio

20 cytopathology, and molecular alterations of pancreatic ductal adenocarcinoma and its precursors.

21 of chronic pancreatitis and occurs in 25% of pancreatic ductal adenocarcinomas and 40% of acinar cell

22 s and murine models of renal cell carcinoma, pancreatic ductal adenocarcinoma, and melanoma triggered

23 We use pancreatic ductal adenocarcinoma as an in vitro and an i

24 Patients undergoing pancreatectomy for pancreatic ductal adenocarcinoma between 2000 and 2013 w

25 OCR were DUOX 1 and 2, which are silenced in pancreatic ductal adenocarcinoma, but upregulated with P

26 Pancreatic ductal adenocarcinoma carries a dismal progno

27 those for managing recalcitrant tumors like pancreatic ductal adenocarcinoma, cause off-target toxic

28 Importantly, in pancreatic ductal adenocarcinoma cell models, MAGEA6 sup

29 the metabolic requirement of RAS-transformed pancreatic ductal adenocarcinoma cells (PDACs).

30 In 3 independent pancreatic ductal adenocarcinoma cohorts (total particip

31 advances show the accelerated pace at which pancreatic ductal adenocarcinoma drugs are achieving suc

32 ectors, as attractive therapeutic targets in pancreatic ductal adenocarcinoma, especially in BAP1-def

33 Pancreatic ductal adenocarcinoma, even when diagnosed ea

34 Human pancreatic ductal adenocarcinoma has reduced levels of P

35 adenocarcinoma incidence is rising and that pancreatic ductal adenocarcinoma has the highest case-fa

36 Whole-exome and whole-genome sequencing of pancreatic ductal adenocarcinomas have confirmed the cri

37 es that are effective for most patients with pancreatic ductal adenocarcinoma, important incremental

38 s the regression, and delays the regrowth of pancreatic ductal adenocarcinoma in a patient-derived xe

39 l be major breakthroughs in the treatment of pancreatic ductal adenocarcinoma in the next 5-10 years.

40 imate, in conjunction with the findings that pancreatic ductal adenocarcinoma incidence is rising and

41 intraductal papillary mucosal neoplasms and pancreatic ductal adenocarcinoma including the character

42 Pancreatic ductal adenocarcinoma is a notoriously diffic

43 Pancreatic ductal adenocarcinoma is an aggressive cancer

44 Purpose Metastatic pancreatic ductal adenocarcinoma is characterized by exc

45 stration, olaparib for germline BRCA-mutated pancreatic ductal adenocarcinoma is expected to be appro

46 Gemcitabine delivery to pancreatic ductal adenocarcinoma is limited by poor phar

47 Pancreatic ductal adenocarcinoma is one of the deadliest

48 Pancreatic ductal adenocarcinoma is one of the most aggr

49 Pancreatic ductal adenocarcinoma is one of the most inva

50 Pancreatic ductal adenocarcinoma is projected to become

51 Pancreatic ductal adenocarcinoma is the predominant neop

52 Pancreatic ductal adenocarcinoma is the seventh leading

53 requently following preoperative therapy for pancreatic ductal adenocarcinoma, it is associated with

54 the factors that lead to the development of pancreatic ductal adenocarcinoma, its progression, and t

55 In a pancreatic ductal adenocarcinoma model, ROS limitation t

56 d that B7-H3.CAR-Ts controlled the growth of pancreatic ductal adenocarcinoma, ovarian cancer and neu

57 tissue homeostasis in pancreatic injury and pancreatic ductal adenocarcinoma pathogenesis.

58 Pancreatic ductal adenocarcinoma (PDA) and chronic pancr

59 e optimal neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma (PDA) and the impact on

60 ent on the uptake of extracellular proteins, pancreatic ductal adenocarcinoma (PDA) cells were select

61 Lineage plasticity is a prominent feature of pancreatic ductal adenocarcinoma (PDA) cells, which can

62 AIMS: Approximately 50% of all patients with pancreatic ductal adenocarcinoma (PDA) develop diabetes

63 The stroma of pancreatic ductal adenocarcinoma (PDA) forms a major bar

64 Although pancreatic ductal adenocarcinoma (PDA) has historically

65 Pancreatic ductal adenocarcinoma (PDA) is a deadly cance

66 Pancreatic ductal adenocarcinoma (PDA) is a heterogeneou

67 Pancreatic ductal adenocarcinoma (PDA) is a lethal malig

68 Pancreatic ductal adenocarcinoma (PDA) is among the most

69 Pancreatic ductal adenocarcinoma (PDA) is an aggressive

70 The tumor microenvironment (TME) in pancreatic ductal adenocarcinoma (PDA) is characterized

71 The immune microenvironment of pancreatic ductal adenocarcinoma (PDA) is comprised of a

72 though the estimated time for development of pancreatic ductal adenocarcinoma (PDA) is more than 20 y

73 Pancreatic ductal adenocarcinoma (PDA) is one of the mos

74 cribe lipid accumulation in the TME areas of pancreatic ductal adenocarcinoma (PDA) populated by CD8+

75 Pancreatic ductal adenocarcinoma (PDA) remains one of th

76 Pancreatic ductal adenocarcinoma (PDA) was responsible f

77 ently been implicated in the pathogenesis of pancreatic ductal adenocarcinoma (PDA)(1).

78 Using models of pancreatic ductal adenocarcinoma (PDA), we show that a d

79 ive extracellular matrix and defines primary pancreatic ductal adenocarcinoma (PDA).

80 modulates the extracellular matrix (ECM) in pancreatic ductal adenocarcinoma (PDA).

81 er.Obesity is an established risk factor for pancreatic ductal adenocarcinoma (PDA).

82 tumor cells may improve the poor outcome of pancreatic ductal adenocarcinoma (PDA).

83 sion of exosomes at the distal tumor site of pancreatic ductal adenocarcinoma (PDAC) ablated the deve

84 Pancreatic ductal adenocarcinoma (PDAC) after complete s

85 ne resectable (BR) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC) after neoadjuvan

86 emcitabine alone in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) and a Karnofsky

87 Pancreatic ductal adenocarcinoma (PDAC) and cholangiocar

88 ge mitochondria and are cystic precursors to pancreatic ductal adenocarcinoma (PDAC) and cholangiocar

89 and induced cell death in KRAS-mutated human pancreatic ductal adenocarcinoma (PDAC) and colon cancer

90 nsmembrane mucin, is aberrantly expressed in pancreatic ductal adenocarcinoma (PDAC) and generally co

91 LCN2 is upregulated in patients with pancreatic ductal adenocarcinoma (PDAC) and in obese ind

92 g that cAMP pathway is commonly activated in pancreatic ductal adenocarcinoma (PDAC) and its premalig

93 pithelial-to-mesenchymal transition (EMT) in Pancreatic Ductal Adenocarcinoma (PDAC) and of mesenchym

94 s and have emerged as therapeutic targets in pancreatic ductal adenocarcinoma (PDAC) and other cancer

95 reduced metastasis and prolonged survival in pancreatic ductal adenocarcinoma (PDAC) and our genomic

96 l variation in use of surgery for stage I-II pancreatic ductal adenocarcinoma (PDAC) and the associat

97 ance of the SIII in patients with resectable pancreatic ductal adenocarcinoma (PDAC) and the effects

98 KRAS are the hallmark genetic alterations in pancreatic ductal adenocarcinoma (PDAC) and the key driv

99 The relationships between diabetes and pancreatic ductal adenocarcinoma (PDAC) are complex.

100 Early-detection tests for pancreatic ductal adenocarcinoma (PDAC) are needed.

101 ch chronic stress promote the development of pancreatic ductal adenocarcinoma (PDAC) are poorly defin

102 ying adaptive targeted therapy resistance in pancreatic ductal adenocarcinoma (PDAC) are poorly under

103 tudies have reported a role for HNF1alpha in pancreatic ductal adenocarcinoma (PDAC) but it is contro

104 Here, we present non-invasive detection of pancreatic ductal adenocarcinoma (PDAC) by 5-hydroxymeth

105 We have shown that pancreatic ductal adenocarcinoma (PDAC) cell lines exhib

106 Pancreatic ductal adenocarcinoma (PDAC) cells (PCC) have

107 perates to prevent cellular proliferation in pancreatic ductal adenocarcinoma (PDAC) cells, patient-d

108 nd remodeling of the extracellular matrix in pancreatic ductal adenocarcinoma (PDAC) cells.

109 h CS-GRP78 contributes to radioresistance in pancreatic ductal adenocarcinoma (PDAC) cells.

110 ternative route for discharging lactate from pancreatic ductal adenocarcinoma (PDAC) cells.

111 tic vesicular stomatitis virus (VSV) against pancreatic ductal adenocarcinoma (PDAC) cells.

112 f epithelial-mesenchymal transition (EMT) in pancreatic ductal adenocarcinoma (PDAC) cells.

113 ng metabolic abnormalities that occur before pancreatic ductal adenocarcinoma (PDAC) diagnosis could

114 and to liver metastasis, which in turn makes pancreatic ductal adenocarcinoma (PDAC) difficult to tre

115 unotherapy has only limited efficacy against pancreatic ductal adenocarcinoma (PDAC) due to the prese

116 The genome of pancreatic ductal adenocarcinoma (PDAC) frequently conta

117 RA) reprograms pancreatic stroma to suppress pancreatic ductal adenocarcinoma (PDAC) growth.

118 Pancreatic ductal adenocarcinoma (PDAC) has a 5-year sur

119 Pancreatic ductal adenocarcinoma (PDAC) has a dismal pro

120 Pancreatic ductal adenocarcinoma (PDAC) has a dismal pro

121 Pancreatic ductal adenocarcinoma (PDAC) has generally a

122 Pancreatic ductal adenocarcinoma (PDAC) has prominent ex

123 Pancreatic ductal adenocarcinoma (PDAC) has single-digit

124 Pancreatic ductal adenocarcinoma (PDAC) has the worst pr

125 Pancreatic ductal adenocarcinoma (PDAC) has the worst pr

126 Patients with metastatic pancreatic ductal adenocarcinoma (PDAC) have an average

127 Patients with pancreatic ductal adenocarcinoma (PDAC) have high plasma

128 mprovements in the outcomes of patients with pancreatic ductal adenocarcinoma (PDAC) have lagged behi

129 An increasing number of patients with pancreatic ductal adenocarcinoma (PDAC) have undergone r

130 We also imaged mice with pancreatic ductal adenocarcinoma (PDAC) in which NJB2 wa

131 Transcriptional profiling has defined pancreatic ductal adenocarcinoma (PDAC) into distinct su

132 Pancreatic ductal adenocarcinoma (PDAC) is a genetically

133 Pancreatic ductal adenocarcinoma (PDAC) is a highly aggr

134 Pancreatic ductal adenocarcinoma (PDAC) is a highly desm

135 Pancreatic ductal adenocarcinoma (PDAC) is a highly leth

136 Pancreatic ductal adenocarcinoma (PDAC) is a highly mali

137 Pancreatic ductal adenocarcinoma (PDAC) is a leading cau

138 Pancreatic ductal adenocarcinoma (PDAC) is a leading cau

139 Pancreatic ductal adenocarcinoma (PDAC) is a leading cau

140 Pancreatic ductal adenocarcinoma (PDAC) is a lethal canc

141 Pancreatic ductal adenocarcinoma (PDAC) is a lethal mali

142 Pancreatic ductal adenocarcinoma (PDAC) is a therapy rec

143 Pancreatic ductal adenocarcinoma (PDAC) is an aggressive

144 Pancreatic ductal adenocarcinoma (PDAC) is an aggressive

145 Pancreatic Ductal Adenocarcinoma (PDAC) is an aggressive

146 Pancreatic ductal adenocarcinoma (PDAC) is an aggressive

147 Pancreatic ductal adenocarcinoma (PDAC) is an aggressive

148 Pancreatic ductal adenocarcinoma (PDAC) is associated wi

149 Even though pancreatic ductal adenocarcinoma (PDAC) is associated wi

150 Pancreatic ductal adenocarcinoma (PDAC) is associated wi

151 Pancreatic ductal adenocarcinoma (PDAC) is associated wi

152 Pancreatic ductal adenocarcinoma (PDAC) is associated wi

153 Pancreatic ductal adenocarcinoma (PDAC) is characterized

154 Pancreatic ductal adenocarcinoma (PDAC) is characterized

155 Pancreatic ductal adenocarcinoma (PDAC) is characterized

156 KRAS mutant pancreatic ductal adenocarcinoma (PDAC) is characterized

157 Pancreatic ductal adenocarcinoma (PDAC) is characterized

158 Pancreatic ductal adenocarcinoma (PDAC) is considered to

159 overall five-year survival of patients with pancreatic ductal adenocarcinoma (PDAC) is dismal, there

160 Pancreatic ductal adenocarcinoma (PDAC) is driven by co-

161 Pancreatic ductal adenocarcinoma (PDAC) is driven by met

162 Pancreatic ductal adenocarcinoma (PDAC) is frequently ac

163 Pancreatic ductal adenocarcinoma (PDAC) is highly resist

164 Pancreatic ductal adenocarcinoma (PDAC) is increasing in

165 Pancreatic ductal adenocarcinoma (PDAC) is known for its

166 Pancreatic ductal adenocarcinoma (PDAC) is notorious for

167 Pancreatic ductal adenocarcinoma (PDAC) is one of the de

168 Pancreatic ductal adenocarcinoma (PDAC) is one of the de

169 Pancreatic ductal adenocarcinoma (PDAC) is one of the mo

170 to its late diagnosis and dismal prognosis, pancreatic ductal adenocarcinoma (PDAC) is one of the mo

171 Pancreatic ductal adenocarcinoma (PDAC) is one of the mo

172 Pancreatic ductal adenocarcinoma (PDAC) is one of the mo

173 Metastatic pancreatic ductal adenocarcinoma (PDAC) is one of the mo

174 efficacy of systemic cancer therapeutics in pancreatic ductal adenocarcinoma (PDAC) is partly attrib

175 Pancreatic ductal adenocarcinoma (PDAC) is predicted to

176 Pancreatic ductal adenocarcinoma (PDAC) is projected to

177 Advanced pancreatic ductal adenocarcinoma (PDAC) is resistant to

178 Pancreatic ductal adenocarcinoma (PDAC) is still one of

179 Pancreatic ductal adenocarcinoma (PDAC) is typically dia

180 Pancreatic ductal adenocarcinoma (PDAC) lethality is due

181 Pancreatic ductal adenocarcinoma (PDAC) metastasizes to

182 Using a pancreatic ductal adenocarcinoma (PDAC) model, we show t

183 investigated the ontogeny of TAMs in murine pancreatic ductal adenocarcinoma (PDAC) models.

184 In the well-established pancreatic ductal adenocarcinoma (PDAC) mouse model, exp

185 ly invasive distal pancreatectomy (MIDP) for pancreatic ductal adenocarcinoma (PDAC) on outcome by a

186 r-associated macrophages in a mouse model of pancreatic ductal adenocarcinoma (PDAC) originate from b

187 , we found that in cancer cells derived from pancreatic ductal adenocarcinoma (PDAC) PAR2 protein is

188 rapies have demonstrated limited efficacy in pancreatic ductal adenocarcinoma (PDAC) patients despite

189 Pancreatic ductal adenocarcinoma (PDAC) patients have po

190 Five-year survival for pancreatic ductal adenocarcinoma (PDAC) patients remains

191 Tissue architecture contributes to pancreatic ductal adenocarcinoma (PDAC) phenotypes.

192 Most patients with pancreatic ductal adenocarcinoma (PDAC) present with sym

193 multiple factors are known to contribute to pancreatic ductal adenocarcinoma (PDAC) progression, the

194 preoperative therapy and pancreatectomy for pancreatic ductal adenocarcinoma (PDAC) prolongs surviva

195 Pancreatic ductal adenocarcinoma (PDAC) remains a challe

196 Pancreatic ductal adenocarcinoma (PDAC) remains a highly

197 Pancreatic ductal adenocarcinoma (PDAC) remains a lethal

198 Pancreatic ductal adenocarcinoma (PDAC) remains one of t

199 Pancreatic ductal adenocarcinoma (PDAC) remains one of t

200 The prognosis for pancreatic ductal adenocarcinoma (PDAC) remains poor des

201 Pancreatic ductal adenocarcinoma (PDAC) remains recalcit

202 Pancreatic ductal adenocarcinoma (PDAC) represents an im

203 Pancreatic ductal adenocarcinoma (PDAC) responds poorly

204 By contrast, neoantigen expression in pancreatic ductal adenocarcinoma (PDAC) results in exace

205 Pancreatic ductal adenocarcinoma (PDAC) shows great cell

206 er metastatic potential than the more common pancreatic ductal adenocarcinoma (PDAC) subtype.

207 n multi-spectral images of multiplex-labeled pancreatic ductal adenocarcinoma (PDAC) tissue samples.

208 ls of KDM3A and DCLK1 messenger RNA in human pancreatic ductal adenocarcinoma (PDAC) tissues and asso

209 patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) treated with FOL

210 metabolic tracing to demonstrate that mouse pancreatic ductal adenocarcinoma (PDAC) tumors and human

211 Here, we provide evidence that a subset of pancreatic ductal adenocarcinoma (PDAC) tumors are wired

212 Pancreatic ductal adenocarcinoma (PDAC) tumors have a nu

213 Cells in pancreatic ductal adenocarcinoma (PDAC) undergo autophag

214 ine resectable (BR) or locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC) undergoing total

215 s associated with humoral immune response in pancreatic ductal adenocarcinoma (PDAC) using in-depth p

216 hereas a dilated pancreatic duct (>3 mm) and pancreatic ductal adenocarcinoma (PDAC) were associated

217 n the management of patients with resectable pancreatic ductal adenocarcinoma (PDAC) when risks of po

218 ajority of human cancers, and in over 70% of pancreatic ductal adenocarcinoma (PDAC)(1,2).

219 modestly improved the survival prospects of pancreatic ductal adenocarcinoma (PDAC), additional enga

220 Pancreatic ductal adenocarcinoma (PDAC), although a rare

221 in the proto-oncogene KRAS are a hallmark of pancreatic ductal adenocarcinoma (PDAC), an aggressive m

222 is deemed instrumental to the progression of pancreatic ductal adenocarcinoma (PDAC), as exemplified

223 As the major feature of pancreatic ductal adenocarcinoma (PDAC), desmoplastic st

224 djuvant radiotherapy (RT) after resection of pancreatic ductal adenocarcinoma (PDAC), especially for

225 ains a primary challenge in the treatment of pancreatic ductal adenocarcinoma (PDAC), exploiting oxid

226 Pancreatic ductal adenocarcinoma (PDAC), like many KRAS-

227 o a dearth of precision-medicine research in pancreatic ductal adenocarcinoma (PDAC), the main type o

228 Serial biopsy of pancreatic ductal adenocarcinoma (PDAC), to chart tumour

229 h 1 (PD-1) inhibitors have limited effect in pancreatic ductal adenocarcinoma (PDAC), underscoring th

230 In a mouse model of pancreatic ductal adenocarcinoma (PDAC), we observed ear

231 To expand the TAA landscape of pancreatic ductal adenocarcinoma (PDAC), we performed ta

232 system x(C) (-) is a critical dependency of pancreatic ductal adenocarcinoma (PDAC), which is a lead

233 However, in pancreatic ductal adenocarcinoma (PDAC), which is resist

234 or HNF1A harbors susceptibility variants for pancreatic ductal adenocarcinoma (PDAC), while KDM6A, en

235 besity is a major modifiable risk factor for pancreatic ductal adenocarcinoma (PDAC), yet how and whe

236 hanisms that regulate AXL over-expression in pancreatic ductal adenocarcinoma (PDAC).

237 ssor locus make CDK4/6 a potential target in pancreatic ductal adenocarcinoma (PDAC).

238 onmalignant cell type in the stroma of human pancreatic ductal adenocarcinoma (PDAC).

239 n oncogenic Kras murine model of spontaneous pancreatic ductal adenocarcinoma (PDAC).

240 wing neoadjuvant chemoradiation for advanced pancreatic ductal adenocarcinoma (PDAC).

241 xpression is reduced in both human and mouse pancreatic ductal adenocarcinoma (PDAC).

242 may contribute to stagnant survival rates in pancreatic ductal adenocarcinoma (PDAC).

243 ineffective for improving early detection of pancreatic ductal adenocarcinoma (PDAC).

244 mportant prognostic factor for patients with pancreatic ductal adenocarcinoma (PDAC).

245 colytic viruses are promising agents against pancreatic ductal adenocarcinoma (PDAC).

246 signaling critically promotes the growth of pancreatic ductal adenocarcinoma (PDAC).

247 distal pancreatectomy (ODP) in patients with pancreatic ductal adenocarcinoma (PDAC).

248 anifest in multiple cancers, with a focus on pancreatic ductal adenocarcinoma (PDAC).

249 and attenuates cachexia in murine models of pancreatic ductal adenocarcinoma (PDAC).

250 289 patients to characterize progression of pancreatic ductal adenocarcinoma (PDAC).

251 equent amplification of USP21 (22%) in human pancreatic ductal adenocarcinoma (PDAC).

252 onditions promote chemotherapy resistance in pancreatic ductal adenocarcinoma (PDAC).

253 ism pathways were shown to be deregulated in pancreatic ductal adenocarcinoma (PDAC).

254 and p16 inactivation are required to develop pancreatic ductal adenocarcinoma (PDAC).

255 care in the adjuvant treatment of resectable pancreatic ductal adenocarcinoma (PDAC).

256 anIN1) lesions rarely become fully malignant pancreatic ductal adenocarcinoma (PDAC).

257 was also expressed in many tumors including pancreatic ductal adenocarcinoma (PDAC).

258 ineffective for improving early detection of pancreatic ductal adenocarcinoma (PDAC).

259 itions, is a major susceptibility factor for pancreatic ductal adenocarcinoma (PDAC).

260 pithelial neoplasias (PanINs) and ultimately pancreatic ductal adenocarcinoma (PDAC).

261 ol local tumor spread and micrometastasis of pancreatic ductal adenocarcinoma (PDAC).

262 ng and dysfunction in a preclinical model of pancreatic ductal adenocarcinoma (PDAC).

263 chronic inflammatory intestinal diseases and pancreatic ductal adenocarcinoma (PDAC).

264 PanIN) formation yet prevents progression to pancreatic ductal adenocarcinoma (PDAC).

265 trols the development and differentiation of pancreatic ductal adenocarcinoma (PDAC).

266 a samples obtained from patients affected by pancreatic ductal adenocarcinoma (PDAC, n = 58), pancrea

267 Pancreatic ductal adenocarcinomas (PDAC) are deadly on a

268 KRAS mutations are present in over 90% of pancreatic ductal adenocarcinomas (PDAC), and drive thei

269 ID1A mutations occur in approximately 10% of pancreatic ductal adenocarcinomas (PDAC), but whether th

270 Pancreatic cancer, mostly pancreatic ductal adenocarcinomas (PDAC), is one of the

271 dulating heterogeneity in pancreatic cancer (pancreatic ductal adenocarcinoma [PDAC]) model systems,

272 Pancreatic cancer (pancreatic ductal adenocarcinoma, PDAC) is aggressive an

273 lar matrix (D-ECM), is a puzzling feature of pancreatic ductal adenocarcinoma (PDACs).

274 Pancreatic ductal adenocarcinomas (PDACs) are characteri

275 Pancreatic ductal adenocarcinomas (PDACs) are classicall

276 Pancreatic ductal adenocarcinomas (PDACs) are hypovascul

277 llenge to select treatment for patients with pancreatic ductal adenocarcinomas (PDACs) based on genom

278 Five percent to 9% of pancreatic ductal adenocarcinomas (PDACs) develop in pat

279 Most pancreatic ductal adenocarcinomas (PDACs) express an act

280 Metastatic pancreatic ductal adenocarcinomas (PDACs) had a lower in

281 We found that pancreatic ductal adenocarcinomas (PDACs) overexpress th

282 Here we show that ILC2s infiltrate pancreatic ductal adenocarcinomas (PDACs) to activate ti

283 to comprehensively analyze APA events in 148 pancreatic ductal adenocarcinomas (PDACs).

284 ncerous cystic lesions that can develop into pancreatic ductal adenocarcinomas (PDACs).

285 (dMMR) is detected in a small proportion of pancreatic ductal adenocarcinomas (PDACs).

286 ating mutations in KRAS are detected in most pancreatic ductal adenocarcinomas (PDACs).

287 analyze somatic noncoding alterations in 308 pancreatic ductal adenocarcinomas (PDAs) and identify co

288 rent understanding of the pathophysiology of pancreatic ductal adenocarcinoma, recent advances in the

289 (AAV)-driven somatic genome-editing model of pancreatic ductal adenocarcinoma reported by Ideno et al

290 clear definition of "early recurrence" after pancreatic ductal adenocarcinoma resection is currently

291 abilized by CDK5-mediated phosphorylation in pancreatic ductal adenocarcinoma, resulting in the dereg

292 nalyzed ductal and neuroendocrine markers in pancreatic ductal adenocarcinoma, revealing heterogeneou

293 Given the likely systemic nature of pancreatic ductal adenocarcinoma, the oncologic benefit

294 Levels of PRKD1 were reduced in human pancreatic ductal adenocarcinoma tissues compared with n

295 lucose uptake, and glycolysis in three human pancreatic ductal adenocarcinoma tumor xenografts with d

296 Here we demonstrate that, within colon and pancreatic ductal adenocarcinoma tumors, efficient strom

297 A highly aggressive subset of pancreatic ductal adenocarcinomas undergo trans-differen

298 ike cells isolated from patients affected by pancreatic ductal adenocarcinoma, was observed, pointing

299 went potentially curative pancreatectomy for pancreatic ductal adenocarcinoma were examined.

300 patients with histopathologically confirmed pancreatic ductal adenocarcinoma who received preoperati